1. Catalog
  2. Nodes
  3. a(CHEBI:cevimeline)

a(CHEBI:cevimeline)

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
cevimeline
Namespace
chebi
Namespace Version
20180906
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns

Appears in Networks 1

M1 muscarinic acetylcholine receptor in Alzheimer’s disease v1.0.0

This file encodes the article M1 muscarinic acetylcholine receptor in Alzheimer’s disease by Jiang et al, 2014

In-Edges 0

Out-Edges 8

a(CHEBI:cevimeline) decreases a(CHEBI:"amyloid-beta polypeptide 42") View Subject | View Object

Administration of AF267B and AF102B (Cevimeline, EVOXACTM), an M1 mAChRselective agonist once prescribed for the treatment of Sjogren’s syndrome, decreases Abeta42 levels in the cerebral spinal fluid (CSF) of rabbits without affecting APP PubMed:24590577

Appears in Networks:
Annotations
MeSH
Cerebrospinal Fluid

a(CHEBI:cevimeline) decreases path(MESH:"Sjogren's Syndrome") View Subject | View Object

Administration of AF267B and AF102B (Cevimeline, EVOXACTM), an M1 mAChRselective agonist once prescribed for the treatment of Sjogren’s syndrome, decreases Abeta42 levels in the cerebral spinal fluid (CSF) of rabbits without affecting APP PubMed:24590577

Appears in Networks:
Annotations
MeSH
Cerebrospinal Fluid

a(CHEBI:cevimeline) decreases a(CHEBI:"amyloid-beta") View Subject | View Object

Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia PubMed:24590577

Appears in Networks:
Annotations
MeSH
Cerebrospinal Fluid
MeSH
Alzheimer Disease

a(CHEBI:cevimeline) causesNoChange a(HBP:"sAPP-alpha") View Subject | View Object

Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia PubMed:24590577

Appears in Networks:
Annotations
MeSH
Cerebrospinal Fluid
MeSH
Alzheimer Disease

a(CHEBI:cevimeline) increases path(MESH:Confusion) View Subject | View Object

Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia PubMed:24590577

Appears in Networks:
Annotations
MeSH
Cerebrospinal Fluid
MeSH
Alzheimer Disease

a(CHEBI:cevimeline) increases path(MESH:Diarrhea) View Subject | View Object

Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia PubMed:24590577

Appears in Networks:
Annotations
MeSH
Cerebrospinal Fluid
MeSH
Alzheimer Disease

a(CHEBI:cevimeline) increases path(MESH:Asthenia) View Subject | View Object

Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia PubMed:24590577

Appears in Networks:
Annotations
MeSH
Cerebrospinal Fluid
MeSH
Alzheimer Disease

a(CHEBI:cevimeline) increases path(MESH:"Gastrointestinal Diseases") View Subject | View Object

Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia PubMed:24590577

Appears in Networks:
Annotations
MeSH
Cerebrospinal Fluid
MeSH
Alzheimer Disease

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.